424 research outputs found
Principal Aspects of Olbian History in Works of L.M. Slavin
No full textСтаттю присвячено загальному огляду головних питань з історії Ольвії, які вивчав Л.М. Славін, у контексті
минулих і сучасних досліджень.Научная деятельность Л.М. Славина была всесторонней, однако на первое место он всегда ставил интерпретацию и
хронологию археологических памятников. Вместе с тем ему принадлежит много исторических работ. Самой важной
научно-теоретической разработкой Л.М. Славина была общеисторическая периодизация Ольвии. Л.М. Славин первым
обосновал принципы создания исторической периодизации. Он считал целесообразным разделить историю Ольвии
на ряд периодов, качественно отличающихся друг от друга прежде всего по признакам экономического развития, социально-политической жизни, исторических судеб. Ученый впервые попытался применить комплексную методику
исследования источников для каждого из пяти выделенных им периодов с их подробной характеристикой. В своих
обобщающих работах Л.М. Славин оставил много убедительных выводов и соображений относительно разных вопросов
исторического, экономического и культурного развития Ольвии.Research activity of L.M. Slavin was comprehensive, though his principal aim was the interpretation and chronology
of archaeological monuments. In addition, he was the author of many historical works. The most important theoretical
research development of L.M. Slavin was the general historical periodization of Olbia. L.M. Slavin was the first
who substantiated the principles for historical periodization. He considered that it was expedient to divide the
history of Olbia into several periods first of all on the basis of the evidence of economic development, social and
political life, and historic destinies. Also he tried to apply the comprehensive methodology of monuments research
for each of five distinguished periods and for their detailed description
sj-xlsx-5-opp-10.1177_10781552231180875 - Supplemental material for Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis
No full textSupplemental material, sj-xlsx-5-opp-10.1177_10781552231180875 for Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis by Marliese Alexander, Kim Jachno, Kelly-Anne Phillips and
John F Seymour, Monica A Slavin, Ada Cheung, Vivian Shen, Dana Maarouf, Rory Wolfe, Senthil Lingaratnam in Journal of Oncology Pharmacy Practice</p
sj-xlsx-4-opp-10.1177_10781552231180875 - Supplemental material for Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis
No full textSupplemental material, sj-xlsx-4-opp-10.1177_10781552231180875 for Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis by Marliese Alexander, Kim Jachno, Kelly-Anne Phillips and
John F Seymour, Monica A Slavin, Ada Cheung, Vivian Shen, Dana Maarouf, Rory Wolfe, Senthil Lingaratnam in Journal of Oncology Pharmacy Practice</p
sj-docx-6-opp-10.1177_10781552231180875 - Supplemental material for Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis
No full textSupplemental material, sj-docx-6-opp-10.1177_10781552231180875 for Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis by Marliese Alexander, Kim Jachno, Kelly-Anne Phillips and
John F Seymour, Monica A Slavin, Ada Cheung, Vivian Shen, Dana Maarouf, Rory Wolfe, Senthil Lingaratnam in Journal of Oncology Pharmacy Practice</p
sj-xlsx-1-opp-10.1177_10781552231180875 - Supplemental material for Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis
No full textSupplemental material, sj-xlsx-1-opp-10.1177_10781552231180875 for Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis by Marliese Alexander, Kim Jachno, Kelly-Anne Phillips and
John F Seymour, Monica A Slavin, Ada Cheung, Vivian Shen, Dana Maarouf, Rory Wolfe, Senthil Lingaratnam in Journal of Oncology Pharmacy Practice</p
sj-xlsx-2-opp-10.1177_10781552231180875 - Supplemental material for Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis
No full textSupplemental material, sj-xlsx-2-opp-10.1177_10781552231180875 for Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis by Marliese Alexander, Kim Jachno, Kelly-Anne Phillips and
John F Seymour, Monica A Slavin, Ada Cheung, Vivian Shen, Dana Maarouf, Rory Wolfe, Senthil Lingaratnam in Journal of Oncology Pharmacy Practice</p
sj-xlsx-3-opp-10.1177_10781552231180875 - Supplemental material for Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis
No full textSupplemental material, sj-xlsx-3-opp-10.1177_10781552231180875 for Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis by Marliese Alexander, Kim Jachno, Kelly-Anne Phillips and
John F Seymour, Monica A Slavin, Ada Cheung, Vivian Shen, Dana Maarouf, Rory Wolfe, Senthil Lingaratnam in Journal of Oncology Pharmacy Practice</p
Personality of L.M. Slavin on the materials of Scientific Archive of IA NAS of Ukraine
No full textСтаттю написано на основі архівних матеріалів, що змальовують Л.М. Славіна як вченого і неординарну особистість. У науковий обіг введено невідомі архівні матеріали.В его жизни было четыре главных города: Витебск, где он родился и вырос; Ленинград, в котором прошли его
студенческие годы и началась научная карьера; Киев, где он жил и работал; древняя Ольвия, изучению которой
он посвятил свою жизнь. Уделяя большое внимание подготовке молодых кадров, Л.М. Славин преподавал в Киевском государственном университете им. Т.Г. Шевченко. В первые послевоенные годы Л.М. Славин был директором, а позже — заместителем директора Института археологии УССР; одновременно он возглавлял сектор скифо-античной археологии. Л.М. Славин — автор 151 научной публикации.In the life of L.M. Slavin there were four main cities: Vitebsk, where he was born and grew up, Leningrad, where his
student years passed and the scientific career started, Kyiv, where he worked, and ancient Olbia, to study of which he
devoted all his life. Placing high emphasis on teaching new personnel, L.M. Slavin taught at the State Taras Shevchenko
University of Kyiv. He was an advisor of many authors of dissertations. In early post-war years L.M. Slavin was the
director and later the assistant of a director of Institute of Archaeology of USSR. At the same time he was the head of the
department of Scythian and Sarmatian archaeology. L.M. Slavin was an author of 151 scientific publications
Stenotrophomonas maltophilia: emerging disease patterns and challenges for treatment
No full textStenotrophomonas maltophilia is a ubiquitous organism associated with opportunistic infections. In the immunocompromised host, increasing prevalence and severity of illness is observed, particularly opportunistic bloodstream infections and pneumonia syndromes. In this article, the classification and microbiology are outlined, together with clinical presentation, outcomes and management of infections due to S. maltophilia. Although virulence mechanisms and the genetic basis of antibiotic resistance have been identified, a role for standardized and uniform reporting of antibiotic sensitivity is not defined. Infections due to S. maltophilia have traditionally been treated with trimethoprim–sulfamethoxazole, ticarcillin–clavulanic acid, or fluoroquinolone agents. The use of combination therapies, newer fluoroquinolone agents and tetracycline derivatives is discussed. Finally, measures to prevent transmission of S. maltophilia within healthcare facilities are reported, especially in at-risk patient populations.Iain J. Abbott, Monica A. Slavin, John D. Turnidge, Karin A. Thursky and Leon J. Wort
- …
